EMA validates Pfizer and OPKO’s somatrogon marketing application for review

The European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for Pfizer and OPKO’s somatrogon, for review.

Somatrogon is a long-acting human growth hormone (hGH) molecule, which is intended to be injected once-weekly for the treatment of paediatric patients with growth hormone deficiency (GHD).